Comparison of PD-L1 expression in primary and metastatic lung cancer biopsies Read more about Comparison of PD-L1 expression in primary and metastatic lung cancer biopsies
Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer Read more about Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
Spatial analytics of the tumor microenvironment on double stained immunohistochemistry images using deep learning Read more about Spatial analytics of the tumor microenvironment on double stained immunohistochemistry images using deep learning
Different genomic mutations signatures are associated to specific PD-L1/TMB states on lung cancer with potential value for patients screening for immunotherapy Read more about Different genomic mutations signatures are associated to specific PD-L1/TMB states on lung cancer with potential value for patients screening for immunotherapy
Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status Read more about Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status
A novel cross-site analysis of Vectra® Polaris™ multiplex fluorescence PD-1/PD-L1 immunohistochemistry on colorectal cancer with high and low microsatellite instability Read more about A novel cross-site analysis of Vectra® Polaris™ multiplex fluorescence PD-1/PD-L1 immunohistochemistry on colorectal cancer with high and low microsatellite instability
Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients Read more about Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients
Spatial relationship of tertiary lymphoid structures and PMN MDSCs in bladder cancer and prognostic potential for PD-L1 immunotherapy Read more about Spatial relationship of tertiary lymphoid structures and PMN MDSCs in bladder cancer and prognostic potential for PD-L1 immunotherapy
Predictive Markers Require Thorough Analytic Validation Read more about Predictive Markers Require Thorough Analytic Validation
Real-world PD-L1 test utilization and analytical concordance of the PD-L1 IHC 28-8 and 22C3 assays in patients with breast cancer Read more about Real-world PD-L1 test utilization and analytical concordance of the PD-L1 IHC 28-8 and 22C3 assays in patients with breast cancer